Literature DB >> 24721792

Heterogeneity of clonal expansion and maturation-linked mutation acquisition in hematopoietic progenitors in human acute myeloid leukemia.

R B Walter1, G S Laszlo2, J M Lionberger2, J A Pollard3, K H Harrington2, C J Gudgeon2, M Othus4, S Rafii5, S Meshinchi3, F R Appelbaum6, I D Bernstein3.   

Abstract

Recent technological advances led to an appreciation of the genetic complexity of human acute myeloid leukemia (AML), but underlying progenitor cells remain poorly understood because their rarity precludes direct study. We developed a co-culture method integrating hypoxia, aryl hydrocarbon receptor inhibition and micro-environmental support via human endothelial cells to isolate these cells. X-chromosome inactivation studies of the least mature precursors derived following prolonged culture of CD34(+)/CD33(-) cells revealed polyclonal growth in highly curable AMLs, suggesting that mutations necessary for clonal expansion were acquired in more mature progenitors. Consistently, in core-binding factor (CBF) leukemias with known complementing mutations, immature precursors derived following prolonged culture of CD34(+)/CD33(-) cells harbored neither mutation or the CBF mutation alone, whereas more mature precursors often carried both mutations. These results were in contrast to those with leukemias with poor prognosis that showed clonal dominance in the least mature precursors. These data indicate heterogeneity among progenitors in human AML that may have prognostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24721792      PMCID: PMC4167978          DOI: 10.1038/leu.2014.107

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  50 in total

Review 1.  Genomics of AML: clinical applications of next-generation sequencing.

Authors:  John S Welch; Daniel C Link
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Clonal architecture of secondary acute myeloid leukemia.

Authors:  Matthew J Walter; Dong Shen; Li Ding; Jin Shao; Daniel C Koboldt; Ken Chen; David E Larson; Michael D McLellan; David Dooling; Rachel Abbott; Robert Fulton; Vincent Magrini; Heather Schmidt; Joelle Kalicki-Veizer; Michelle O'Laughlin; Xian Fan; Marcus Grillot; Sarah Witowski; Sharon Heath; John L Frater; William Eades; Michael Tomasson; Peter Westervelt; John F DiPersio; Daniel C Link; Elaine R Mardis; Timothy J Ley; Richard K Wilson; Timothy A Graubert
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

Review 3.  Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.

Authors:  R Majeti
Journal:  Oncogene       Date:  2010-11-15       Impact factor: 9.867

4.  Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia.

Authors:  Nicolas Goardon; Emanuele Marchi; Ann Atzberger; Lynn Quek; Anna Schuh; Shamit Soneji; Petter Woll; Adam Mead; Kate A Alford; Raj Rout; Salma Chaudhury; Amanda Gilkes; Steve Knapper; Kheira Beldjord; Suriya Begum; Susan Rose; Nicola Geddes; Mike Griffiths; Graham Standen; Alexander Sternberg; Jamie Cavenagh; Hannah Hunter; David Bowen; Sally Killick; Lisa Robinson; Andrew Price; Elizabeth Macintyre; Paul Virgo; Alan Burnett; Charles Craddock; Tariq Enver; Sten Eirik W Jacobsen; Catherine Porcher; Paresh Vyas
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 31.743

5.  Stem cell gene expression programs influence clinical outcome in human leukemia.

Authors:  Kolja Eppert; Katsuto Takenaka; Eric R Lechman; Levi Waldron; Björn Nilsson; Peter van Galen; Klaus H Metzeler; Armando Poeppl; Vicki Ling; Joseph Beyene; Angelo J Canty; Jayne S Danska; Stefan K Bohlander; Christian Buske; Mark D Minden; Todd R Golub; Igor Jurisica; Benjamin L Ebert; John E Dick
Journal:  Nat Med       Date:  2011-08-28       Impact factor: 53.440

6.  Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice.

Authors:  Jean-Emmanuel Sarry; Kathleen Murphy; Robin Perry; Patricia V Sanchez; Anthony Secreto; Cathy Keefer; Cezary R Swider; Anne-Claire Strzelecki; Cindy Cavelier; Christian Récher; Véronique Mansat-De Mas; Eric Delabesse; G Danet-Desnoyers; Martin Carroll
Journal:  J Clin Invest       Date:  2010-12-13       Impact factor: 14.808

7.  Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker.

Authors:  Max Jan; Mark P Chao; Adriel C Cha; Ash A Alizadeh; Andrew J Gentles; Irving L Weissman; Ravindra Majeti
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-07       Impact factor: 11.205

8.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

9.  Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Authors:  Li Ding; Timothy J Ley; David E Larson; Christopher A Miller; Daniel C Koboldt; John S Welch; Julie K Ritchey; Margaret A Young; Tamara Lamprecht; Michael D McLellan; Joshua F McMichael; John W Wallis; Charles Lu; Dong Shen; Christopher C Harris; David J Dooling; Robert S Fulton; Lucinda L Fulton; Ken Chen; Heather Schmidt; Joelle Kalicki-Veizer; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Michael C Wendl; Sharon Heath; Mark A Watson; Daniel C Link; Michael H Tomasson; William D Shannon; Jacqueline E Payton; Shashikant Kulkarni; Peter Westervelt; Matthew J Walter; Timothy A Graubert; Elaine R Mardis; Richard K Wilson; John F DiPersio
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962

10.  Frequency of leukemic initiating cells does not depend on the xenotransplantation model used.

Authors:  J Vargaftig; D C Taussig; E Griessinger; F Anjos-Afonso; T A Lister; J Cavenagh; H Oakervee; J Gribben; D Bonnet
Journal:  Leukemia       Date:  2011-09-16       Impact factor: 11.528

View more
  6 in total

1.  A mathematical model of subpopulation kinetics for the deconvolution of leukaemia heterogeneity.

Authors:  María Fuentes-Garí; Ruth Misener; David García-Munzer; Eirini Velliou; Michael C Georgiadis; Margaritis Kostoglou; Efstratios N Pistikopoulos; Nicki Panoskaltsis; Athanasios Mantalaris
Journal:  J R Soc Interface       Date:  2015-07-06       Impact factor: 4.118

Review 2.  Predicting Chemotherapy Resistance in AML.

Authors:  Cecilia C S Yeung; Jerald Radich
Journal:  Curr Hematol Malig Rep       Date:  2017-12       Impact factor: 3.952

Review 3.  Acute Myeloid Leukemia Stem Cells: Origin, Characteristics, and Clinical Implications.

Authors:  Nathaniel A Long; Upendarrao Golla; Arati Sharma; David F Claxton
Journal:  Stem Cell Rev Rep       Date:  2022-01-20       Impact factor: 6.692

Review 4.  Mylotarg has potent anti-leukaemic effect: a systematic review and meta-analysis of anti-CD33 antibody treatment in acute myeloid leukaemia.

Authors:  J Loke; J N Khan; J S Wilson; C Craddock; K Wheatley
Journal:  Ann Hematol       Date:  2014-10-05       Impact factor: 3.673

5.  The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.

Authors:  Kimberly H Harrington; Chelsea J Gudgeon; George S Laszlo; Kathryn J Newhall; Angus M Sinclair; Stanley R Frankel; Roman Kischel; Guang Chen; Roland B Walter
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 6.  Immunotherapy as a Turning Point in the Treatment of Acute Myeloid Leukemia.

Authors:  Anna Aureli; Beatrice Marziani; Tommaso Sconocchia; Maria Ilaria Del Principe; Elisa Buzzatti; Gianmario Pasqualone; Adriano Venditti; Giuseppe Sconocchia
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.